Global Survey Highlights Impact of Plasma-Derived Medicines on Patient Health

WASHINGTON, Oct. 5, 2026 /CourierPR/ -- A new global survey has revealed the profound impact of plasma-derived medicines on patients living with a range of health conditions, with 69% noticing a change in their health, or the health of someone they care for, within a few months of beginning treatment. The survey, conducted by the Plasma Protein Therapeutics Association (PPTA) and analyzed by SSRS, involved more than 1,100 patients, caregivers, healthcare providers, and patient advocates.

The survey highlighted that 87% of patients are confident in the safety and efficacy of plasma-derived medicines. Additionally, 77% of respondents expressed gratitude to plasma donors, underscoring the critical role these donors play in the lives of patients. The findings come as International Plasma Awareness Week (IPAW) begins on October 5, aiming to raise awareness and appreciation for plasma donors and the medicines they make possible.

Plasma-derived medicines are essential for treating a variety of serious medical conditions, including primary immunodeficiencies, bleeding disorders, autoimmune conditions, and neurological and lung-related illnesses. The survey revealed that nearly half of the respondents, or 49%, first received a plasma-derived medicine between the ages of 36 and 64. Among the conditions treated, 46% of respondents received treatment for an immunodeficiency, 18% for a bleeding or blood disorder, 16% for a neurological condition, and 15% for a lung-related illness.

Many patients and their caregivers reported noticing a swift improvement in their health after starting treatment. Specifically, 69% of respondents noticed a change in their health, or the health of someone they care for, within a few months of beginning a plasma-derived medicine, with 26% noticing a change within just a few days. Approximately two in three respondents (67%) reported receiving treatment at least once a month, including 41% who received treatment weekly.

The survey methodology involved 1,167 completed interviews conducted online via SurveyMonkey. The data was formally analyzed in August 2026. PPTA, which represents a sector of the biologics and biotechnology industry, has more than 1,000 plasma collection centers across North America and Europe. The association produces approximately 80% of plasma protein therapies used in the United States and manufactures about 60% of those used in Europe.